Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pulmonology
Volume 2015 (2015), Article ID 498981, 3 pages
http://dx.doi.org/10.1155/2015/498981
Case Report

The Rapid Initiation, Titration, and Transition from Intravenous to Oral Treprostinil in a Patient with Severe Pulmonary Arterial Hypertension

1Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Florida, 2950 Cleveland Clinic Boulevard, Weston, FL 33331, USA
2Department of Internal Medicine, Cleveland Clinic Florida, 2950 Cleveland Clinic Boulevard, Weston, FL 33331, USA

Received 2 July 2015; Accepted 9 September 2015

Academic Editor: Motoshi Takao

Copyright © 2015 James Benjamin Gleason et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Barst, N. Galie, R. Naeije et al., “Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil,” European Respiratory Journal, vol. 28, no. 6, pp. 1195–1203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Lang, M. Gomez-Sanchez, M. Kneussl et al., “Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension,” Chest, vol. 129, no. 6, pp. 1636–1643, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. V. F. Tapson, M. Gomberg-Maitland, V. V. Mclaughlin et al., “Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial,” Chest, vol. 129, no. 3, pp. 683–688, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Hiremath, S. Thanikachalam, K. Parikh et al., “Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial,” Journal of Heart and Lung Transplantation, vol. 29, no. 2, pp. 137–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. J. Barst, L. J. Rubin, and W. A. Long, “A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension,” Pneumologie, vol. 51, no. 10, p. 993, 1997. View at Google Scholar · View at Scopus
  6. G. Simonneau, R. J. Barst, N. Galie et al., “Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 6, pp. 800–804, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. Orenitram [package insert], United Therapeutics Corporation, Silver Spring, Md, USA, 2013, http://www.orenitram.com/dtc/pdf/Orenitram_Full_Prescribing_Information.pdf.
  8. R. J. White, F. Torres, R. Allen et al., “Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension,” Journal of Cardiovascular Pharmacology, vol. 61, no. 6, pp. 474–481, 2013. View at Publisher · View at Google Scholar
  9. L. Peterson, T. Marbury, J. Marier, and K. Laliberte, “An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment,” Journal of Clinical Pharmacy and Therapeutics, vol. 38, no. 6, pp. 518–523, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. Z.-C. Jing, K. Parikh, T. Pulido et al., “Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial,” Circulation, vol. 127, no. 5, pp. 624–633, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. R. L. Benza, M. Gomberg-Maitland, R. Naeije, C. P. Arneson, and I. M. Lang, “Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials,” Journal of Heart and Lung Transplantation, vol. 30, no. 9, pp. 982–989, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. I. R. Preston and H. W. Farber, “Impact of parenteral treprostinil dosing in pulmonary arterial hypertension,” The Journal of Heart and Lung Transplantation, vol. 32, no. 4, supplement, pp. S64–S65, 2013. View at Publisher · View at Google Scholar
  13. J.-L. Vachiéry, N. Hill, D. Zwicke, R. Barst, S. Blackburn, and R. Naeije, “Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension,” Chest, vol. 121, no. 5, pp. 1561–1565, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Gomberg-Maitland, V. F. Tapson, R. L. Benza et al., “Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 12, pp. 1586–1589, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Rubenfire, V. V. McLaughlin, R. P. Allen et al., “Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial,” Chest, vol. 132, no. 3, pp. 757–763, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. R. J. White, M. Chakinala, F. Rischard et al., “Safety and tolerability of transitioning from parenteral treprostinil to oral trepsostinil in patients with pulmonary arterial hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 189, article A2460, 2014, (abstract). View at Google Scholar
  17. United Therapeutics, A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning from Remodulin to Oral Treprostinil in Subjects with Pulmonary Arterial Hypertension, ClinicalTrials.gov, National Library of Medicine, Bethesda, Md, USA, 2012, https://clinicaltrials.gov/ct2/show/NCT01588405.
  18. L. Hansen, F. Rischard, and S. Knoper, “Rapid inpatient titration of intravenous treprostinil for severe pulmonary arterial hypertension,” The Journal of Heart and Lung Transplantation, vol. 33, no. 4, supplement, p. S309, 2014. View at Publisher · View at Google Scholar